Cohen Yuval 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Corbus (CRBP) CEO Yuval Cohen Sells 13,871 Shares
What Happened
Yuval Cohen, CEO of Corbus Pharmaceuticals (CRBP), disposed of 13,871 shares on February 13, 2026 in transactions with a weighted average price of $7.78, generating approximately $107,952 in proceeds. The sale was effected under a Rule 10b5-1 trading plan and was a "sell-to-cover" to satisfy tax withholding obligations related to the vesting and settlement of RSUs, not a discretionary sale.
Key Details
- Transaction date: February 13, 2026. Form 4 filed February 18, 2026 (appears timely under the 2-business-day rule).
- Transaction type/code: Sale (S) — open market or private sale, multiple trades.
- Prices: Weighted average $7.78; individual trades ranged $7.58–$7.96 (report provides weighted avg and range; breakdown available on request).
- Proceeds: Approximately $107,952.
- Holdings: The filing notes the reported holdings include 138,049 unvested RSUs subject to prior vesting schedules; the filing does not specify a separate total beneficial ownership number in the summary provided here.
- Footnotes: F1 — sale pursuant to 10b5-1 plan and mandated by issuer's sell-to-cover election for RSU tax withholding (non-discretionary). F2 — weighted average price and price range; seller will provide per-price breakdown on request. F3 — reference to 138,049 unvested RSUs.
Context
This was a routine sell-to-cover tied to RSU vesting and executed under a pre-established 10b5-1 plan, which typically reflects tax-related mechanics rather than a CEO decision to reduce exposure. For retail investors, mandatory sell-to-cover transactions carry less informational weight about management’s view of the company compared with voluntary open-market purchases.
Insider Transaction Report
- Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]2026-02-13$7.78/sh−13,871$107,952→ 174,316 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.